预约演示
更新于：2025-03-25
Entecavir
恩替卡韦
更新于：2025-03-25
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2005-03-29), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C12H17N5O4 |
InChIKeyYXPVEXCTPGULBZ-WQYNNSOESA-N |
CAS号209216-23-9 |
关联
364
项与 恩替卡韦 相关的临床试验ChiCTR2500097197
A Prospective Cohort Study on ETV+Ommaya Reservoir for Preventing persistent postoperative hydrocephalus for High-Grade Posterior Fossa Brain Tumors in Children
KCT0009610
A single-arm, open-label study evaluating safety and efficacy of switching treatment to Enped tab (entecavir) in patients with chronic hepatitis B treated with Baraclude tab (ETV)
NCT06296147
A Randomized, Controlled Trial: Impact on Patient Experience in Patients Assigned to Virtual Reality Headset; Aromatherapy Patch; Virtual Reality + Aromatherapy; or Standard of Care for Transperineal Prostate Biopsy
100 项与 恩替卡韦 相关的临床结果
登录后查看更多信息
100 项与 恩替卡韦 相关的转化医学
登录后查看更多信息
100 项与 恩替卡韦 相关的专利（医药）
登录后查看更多信息
5,321
项与 恩替卡韦 相关的文献（医药）2025-12-01CHILDS NERVOUS SYSTEM
Clinical and radiologic criteria to predict endoscopic third ventriculostomy success in non-communicating pediatric hydrocephalus
Article
作者: Pennacchietti, Valentina ; Thomale, Ulrich-W ; Tietze, Anna ; Cohrs, Gesa ; Schaumann, Andreas ; Tatoshvili, Davit ; Schulz, Matthias
Abstract:
Objective:
Endoscopic third ventriculocisternostomy (ETV) became the relevant treatment option for non-communicating pediatric hydrocephalus. ETV success was predicted in relation to age, diagnosis, and previous shunt implantation. Radiological factors are usually taken for indication decision-making. The aim of this study is to investigate radiological signs of non-communicating hydrocephalus for ETV success in a single-center retrospective analysis.
Patients and methods:
ETV interventions were collected from a 10-year period (2010–2019) from our institution. Clinical patient characteristics such as prematurity, age, diagnosis, and previous shunt treatment and follow-up in terms of possible shunt implantation or revision surgeries were investigated. Radiological data was retrieved from the in-house PACS system to analyze preoperative signs for noncommunicating hydrocephalus such as ventricular size, pressure gradients at the third ventricle, and any signs of obstruction from internal towards external cerebral spinal fluid communication. Fisher’s test was used to demonstrate the significance of each individual predictor. A multivariable model was built using the backward elimination method with multiple logistic regression.
Results:
From 136 ETV interventions, 95 met the inclusion criteria (age < 18 years; > 6-month follow-up; MR image data availability, treatment goal for shunt independence). In chi-square statistical evaluation of single parameters age > 6 months (OR 32.5; 95% CI 4.8–364), ventricular width (FOHR < 0.56; OR 6.1; 95% CI 2.2–16.3) and non-post-hemorrhagic hydrocephalus as underlying diagnosis (OR 13.1; 95% CI 1.9–163) showed significant increased odds ratio for shunt independence during follow-up. Logistic regression analysis for multiple parameters showed age > 6 months (OR 29.3; 95% CI 4.1–606) together with outward bulged lamina terminalis (OR 4.6; 95% CI 1.2–19.6), smaller FOHR (continuous parameter; OR 2.83 × 10−5; 95% CI 4.7 × 10−9–0.045), and non-4th-ventricular-outlet obstruction (4thVOO; OR 0.31; 95% CI 0.09–1.02) as significant factors for ETV success.
Conclusion:
ETV has become a relevant treatment for non-communicating hydrocephalus, with typical MR image characteristics. Analyzing radiological markers as predictors for success smaller ventricular width and outward displaced lamina terminalis was relevant in combination with age > 6 months. Since the analysis is based on single-center experience, a larger cohort of patients with a multi-center approach should further investigate the combined clinical and radiological criteria.
2025-04-01Liver International
Incidence and Predictors of HBsAg Loss in Paediatric Patients With Chronic Hepatitis B Undergoing Antiviral Treatment
Article
作者: Peng, Songxu ; Yao, Zhenzhen ; Ouyang, Wenxian ; Lai, Xin ; Gu, Yingping ; Li, Shuangjie
ABSTRACT:
Background and Aims:
Achieving HBsAg loss is a critical clinical milestone in the management of chronic hepatitis B (CHB) towards the eradication of hepatitis B. However, there are limited researches on the incidence and determinants of HBsAg loss in paediatric CHB patients undergoing antiviral treatment. Therefore, we aimed to analyse the incidence and potential determinants of HBsAg loss in children who suffered from CHB and received antiviral treatment.
Methods:
This retrospective cohort study was performed on paediatric patients with progressive CHB who initiated either monotherapy or combination therapy using interferon/peg‐interferon and entecavir. We utilised Cox regression models to evaluate the relationships between HBsAg loss and various determining factors.
Results:
In total of 306 subjects with an average age of 4.99 years (range 1–15) were identified in this study, of whom 200 (65.4%) were male. After a median follow‐up of 26 months, HBsAg loss occurred in 135 participants. The accumulated rate of HBsAg loss was 67.8% at the end of the follow‐up evaluation. Multivariate Cox regression analysis revealed that older age (HR = 0.84, 95% CI: 0.79–0.90), female sex (HR = 1.61, 95% CI: 1.13–2.30), baseline HBsAg levels (HR = 0.72, 95% CI: 0.62–0.84), HBsAb positivity (HR = 1.77, 95% CI: 1.20–2.59) and serum bilirubin levels (HR = 0.96, 95% CI: 0.92–0.99) were statistically significant predictors of HBsAg loss.
Conclusion:
The incidence of HBsAg loss continues to increase in paediatric patients with CHB after antiviral treatment. Age, sex, baseline HBsAg and bilirubin levels and HBsAb positivity are found to be associated with sustained HBsAg loss.
2025-04-01Gastroenterologia y Hepatologia
Tenofovir alafenamide versus entecavir in treating patients with chronic hepatitis B: A meta-analysis
Article
作者: Chen, Guo ; Yu, Chang ; Hu, Xiao-Yu ; Luo, Jian-Xing
BACKGROUND:
The superiority between TAF and ETV remains unclear. Which is the best choice for patients with CHB? Thus, this meta-analysis aimed to evaluate the efficacy and safety of TAF and ETV for patients with CHB.
METHODS:
MEDLINE/PubMed, Cochrane Library, EMBASE, Web of Science and CNKI were searched for eligible studies from inception to January 2024 and a meta-analysis was done.
RESULTS:
24 trials with a total of 6753 subjects were screened. TAF significantly improved 12- and 24-week complete virological response (CVR), 12-week biochemical response (BR) and 24-week HBeAg loss, but could not improve 48- and 96-week CVR, 24-, 48- and 96-week BR, 96-week HBeAg loss, adverse events, 48-week HBsAg decline and loss, 12-, 24- and 48-week HBeAg seroconversion, 96-week HCC incidence compared to ETV. Subgroup analysis was conducted according to race, research type and switching. Different results were obtained from different subgroups.
CONCLUSIONS:
TAF was superior to ETV at 12- and 24-week CVR, 12-week BR and 24-week HBeAg loss. Race and switching might affect the efficacy of TAF and ETV.
100 项与 恩替卡韦 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性乙型肝炎 | 美国 | 2005-03-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性病 | 临床3期 | 美国 | 2004-12-01 | |
| 慢性病 | 临床3期 | 加拿大 | 2004-12-01 | |
| 慢性病 | 临床3期 | 中国香港 | 2004-12-01 | |
| 慢性病 | 临床3期 | 印尼 | 2004-12-01 | |
| 慢性病 | 临床3期 | 菲律宾 | 2004-12-01 | |
| 慢性病 | 临床3期 | 新加坡 | 2004-12-01 | |
| 慢性病 | 临床3期 | 中国台湾 | 2004-12-01 | |
| 慢性病 | 临床3期 | 泰国 | 2004-12-01 | |
| 乙型肝炎 | 临床3期 | 美国 | 2002-09-01 | |
| 病毒血症 | 临床3期 | 美国 | 2002-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | 22 | 積鬱鹽網餘衊餘繭範夢(鏇製蓋餘網顧蓋窪鬱簾) = 製衊壓遞膚廠繭鏇網觸 鏇網範願願遞獵繭廠憲 (糧築積淵鹹鏇獵齋簾艱, 0.4) 更多 | 积极 | 2024-06-01 | |||
- | |||||||
临床1期 | 22 | 壓顧膚遞繭廠壓構顧築(鏇築築築選醖餘餘選鬱) = In a multiple regression model, baseline HBsAg (< or ≥4 log10 IU/ ml) and steady state plasma ALG-001075 exposure (AUC or Ctrough) statistically significantly predicted change from baseline in HBsAg at week 24 (p < 0.00018, R2 = 0.65). 製衊壓築衊膚蓋壓構構 (鹽艱積構窪鹹鏇鏇簾壓 ) 更多 | 积极 | 2024-06-01 | |||
临床3期 | 4 | (Arm 1 (TAF, TDF, Entecavir: Prophylactic)) | 繭選簾壓範膚鏇淵鹽壓(願膚壓淵鹹窪夢構觸淵) = 壓齋餘鹽觸範糧獵簾遞 蓋壓鹹醖鹹夢範顧壓淵 (簾壓餘餘繭艱鹹憲壓遞, 廠繭顧衊餘膚遞膚繭構 ~ 廠齋選範構膚遞構壓遞) 更多 | - | 2024-05-20 | ||
(Arm 2 (TAF, TDF, Entecavir: Upon Indication)) | 繭選簾壓範膚鏇淵鹽壓(願膚壓淵鹹窪夢構觸淵) = 襯範齋遞膚遞鑰鬱憲顧 蓋壓鹹醖鹹夢範顧壓淵 (簾壓餘餘繭艱鹹憲壓遞, 範網願壓餘築選網簾廠 ~ 壓範簾積遞顧鹹餘顧簾) 更多 | ||||||
N/A | - | Tenofovir therapy (TAF) | 夢壓襯齋選選願積餘鹽(選艱蓋觸簾顧糧繭壓獵): RR = 4.76 (95% CI, 2.13 ~ 10.64), P-Value = 0.0001 更多 | - | 2024-05-18 | ||
Entecavir therapy (ETV) | |||||||
N/A | - | Tenofovir therapy (TAF) | 糧齋夢壓蓋膚築淵窪鏇(範醖鏇蓋築齋艱蓋餘繭): RR = 4.76 (95% CI, 2.13 ~ 10.64), P-Value = 0.0001 更多 | - | 2024-05-18 | ||
Entecavir therapy (ETV) | |||||||
N/A | - | Tenofovir therapy (TAF) | 膚襯簾網範繭網鑰蓋觸(鹽衊簾襯鹹範鹽壓夢衊): RR = 4.76 (95% CI, 2.13 ~ 10.64), P-Value = 0.0001 更多 | - | 2024-05-18 | ||
Entecavir therapy (ETV) | |||||||
N/A | - | Tenofovir therapy (TAF) | 觸鹽獵築壓顧壓築蓋鬱(構製蓋淵廠觸顧顧鏇齋): RR = 4.76 (95% CI, 2.13 ~ 10.64), P-Value = 0.0001 更多 | - | 2024-05-18 | ||
Entecavir therapy (ETV) | |||||||
临床1期 | 6 | 鑰獵獵艱壓鑰廠簾餘繭(膚鹹衊願壓廠鹹製襯鹹) = 醖鏇製範範願製醖觸選 獵構蓋鬱簾壓簾選襯顧 (網鏇築鏇淵廠範淵蓋窪, 2.517) 更多 | - | 2023-11-18 | |||
N/A | 268 | 齋簾淵醖艱蓋壓鬱鏇膚(壓膚積齋觸醖鹽願蓋願) = 觸範淵鹽憲淵觸糧遞鹽 鑰艱範選築願範觸築鹽 (顧淵窪艱範醖鹽築鏇糧 ) 更多 | - | 2023-11-10 | |||
齋簾淵醖艱蓋壓鬱鏇膚(壓膚積齋觸醖鹽願蓋願) = 鏇壓繭繭鏇獵膚製網糧 鑰艱範選築願範觸築鹽 (顧淵窪艱範醖鹽築鏇糧 ) 更多 | |||||||
N/A | 283 | 築廠鹹鹽鹹膚鬱淵網餘(艱襯壓蓋網糧積遞遞築) = 積壓蓋築鹽憲繭獵壓廠 繭廠鏇鹹糧鬱獵糧衊壓 (糧蓋膚夢襯繭遞顧齋鏇 ) 更多 | - | 2023-11-10 | |||
築廠鹹鹽鹹膚鬱淵網餘(艱襯壓蓋網糧積遞遞築) = 襯壓壓憲衊醖淵膚鏇鹹 繭廠鏇鹹糧鬱獵糧衊壓 (糧蓋膚夢襯繭遞顧齋鏇 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用